MAY 23, 2018 01:10 AM PDT
Potential Treatment for Triple-Negative Breast Cancer
WRITTEN BY: Nouran Amin
2 1 77


Recent research published in the Journal of Clinical Investigation examined the drug Dacogen (decitabine), which was observed to target the growth of cancer and was effective in treating tumors resistant to chemotherapy. The Food and Drug Administration has approved decitabine for treating bone marrow and blood cancers

“Patients whose tumor does not respond well to chemotherapy are known to be at significantly increased risk of recurrent breast cancer and death,” expalins Judy Boughey, MD, a general surgeon at the Cancer Center at the Mayo Clinic in Rochester, Minnesota. “Therefore, our focus is to identify new treatment options for these patients.”

 

 

Breast cancer is responsible for 30 percent of new cancer diagnoses in women in the United States each year. About 1 in 8 women will be diagnosed with invasive breast cancer at some point in their lives. The majority of breast cancers are invasive, which means that the cancer spreads and grows in healthy tissues. This is in comparison to noninvasive breast cancers which remain in the lobules or the milk ducts.

For triple-negative breast cancer (TNBC), the National Breast Cancer Foundation describes this particular cancer as the cells of the tumor that do not include the three most common forms of receptors, which is the HER-2 receptor, estrogen receptors, and progesterone receptors.

Investigators have been studying the potential use for decitabine in solid tumors, however the results are more encouraging than previous trials, exapalisn Cynthia Zahnow, PhD, an associate professor of oncology at the Johns Hopkins University School of Medicine. “We [researchers at Johns Hopkins] published a paper back in 2012 showing that these low doses of these drugs do have an effect in cancer tumors,” she explains, referencing a study published in March 2012 in the journal Cancer Cell.

The study suggested that the therapy could create an anti-tumor “memory” response, and inhibit growth of cancer stem-like cells. In the Mayo research study, the researchers used living xenografts (tissue from breast tumor cells). They found that decitabine can remarkably inhibit the growth of triple-negative breast cancers, however, the response was dependent on the presence of certain critical proteins known as DNA methyl transferase proteins (DNMT), which are present in a certain subset of triple-negative breast cancers.

“If researchers can truly select patients that have high levels of DNMT and show that these drugs are more effective in them, that’s a fantastic discovery,” notes Dr. Zahnow.

Sources: Journal of Clinical Investigation

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
DEC 26, 2017
Drug Discovery
DEC 26, 2017
A Brief Overview of Advances in Systemic Chemo for Pancreatic Cancer
Quick description of first line chemotherapy for pancreatic cancer.
JAN 02, 2018
Drug Discovery
JAN 02, 2018
Anti-Aging Therapies
Summary of key areas of anti-aging research for health and disease management
FEB 26, 2018
Microbiology
FEB 26, 2018
Looking to Bacteria for the Next Antibiotic
Bacteria can be a surprising source of antibiotics. One example is Streptomyces chartreusis, which can secrete a variety of compounds into its environment.
MAY 03, 2018
Drug Discovery
MAY 03, 2018
Treating Migraines with Less Side-Effects
According to a 2013 Global Burden of Disease Study and the World Health Organization (WHO), migraine makes the list as the sixth highest cause worldwide fo
MAY 08, 2018
Drug Discovery
MAY 08, 2018
No More Hair Loss? Osteoporosis Drug Treats Baldness
    According to The University of Manchester's Centre for Dermatology Research, a recent developed drug can lessen the stress experienced by
MAY 09, 2018
Cell & Molecular Biology
MAY 09, 2018
Valuable insights into better protein expression
Pharmaceutical companies, biotech, and academia all have a hand in accelerating our understanding of proteins, whether through wide-ranging proteomics stud
Loading Comments...